Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of a new Novartis meningococcal B recombinant vaccine in 2‑month‑old infants
2009-010106-11Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, meningococcal meningitis and meningococcemia (2 arms), sponsored by Novartis. Primary endpoint: Serum bactericidal antibody response against N. meningitidis serogroup B strains. Started May 2009; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2009-010106-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010106-11.